Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.44 |
| ▸ | FCER2 | P06734 | 3/20 | 0.44 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | MMP7 | P09237 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | MMP8 | P22894 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP14 | P50281 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.33 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6413367 | 0.90 | LMNA (0.40) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL6417248 | 0.87 | MMP1 (0.41) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL7363465 | 0.86 | LMNA (0.37) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL7360690 | 0.84 | FCER2 (0.41) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL7358017 | 0.83 | MMP1 (0.61) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL6420230 | 0.78 | LMNA (0.41) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL7364097 | 0.75 | MMP1 (0.51) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL6417502 | 0.74 | MMP1 (0.50) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL8749681 | 0.72 | MMP1 (0.47) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL7360514 | 0.72 | MMP1 (0.44) | MMP1FCER2MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0667770-B1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARM (GB) | 1997-03-19 | — | — | EP | claimed |
| EP-0667770-A1 | INHIBITION OF TNF PRODUCTION. | BRITISH BIOTECH PHARM (GB) | 1995-08-23 | — | — | EP | claimed |
| WO-1994010990-A1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-05-26 | — | — | WO | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| US-5691382-A | ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-11-25 | — | — | US | disclosed |
| EP-0667770-B1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARM (GB) | 1997-03-19 | — | — | EP | disclosed |
| EP-0667770-A1 | INHIBITION OF TNF PRODUCTION. | BRITISH BIOTECH PHARM (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994010990-A1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP1 20/4885FCER2 4226/4885MMP2 19/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP1 20/4885FCER2 4226/4885MMP2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.